<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="other age groups. The pathogen that causes COVID-19 is the" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV-2), a betacoronavirus that is genetically homologous to"/>
 <result pre="been applied in epitope-carrier fusion construction in HIV vaccine and" exact="malaria" post="vaccine (19,20). The machine learning tool was used to"/>
 <result pre="unrelated pathogens (37,38). The Bacille Calmette-Guerin (BCG), a vaccine for" exact="tuberculosis" post="disease, is currently under clinical evaluation for its ability"/>
 <result pre="of the administered dose (85,86). Since COVID-19 is primarily a" exact="respiratory disease," post="establishing a mucosal immune protection is critical, indicating that"/>
 <result pre="via different mucosal routes. Tomar et al. (2019) demonstrated that" exact="hepatitis" post="B vaccine can induce high IgG titers when delivered"/>
 <result pre="but no titers when delivered intranasally, in contrast to the" exact="influenza" post="vaccine where no difference in titers was observed between"/>
 <result pre="market: Flumist®, Fluenz®, and NasoVac®. FluMist® is a live-attenuated trivalent/quadrivalent" exact="influenza" post="virus vaccine (LAIV) that consists of the influenza A"/>
 <result pre="live-attenuated trivalent/quadrivalent influenza virus vaccine (LAIV) that consists of the" exact="influenza" post="A strains H1N1 and H3N2 and two influenza B"/>
 <result pre="of the influenza A strains H1N1 and H3N2 and two" exact="influenza" post="B strains, protecting against seasonal influenza infections. European Medicines"/>
 <result pre="and H3N2 and two influenza B strains, protecting against seasonal" exact="influenza" post="infections. European Medicines Agency-approved Fluenz® is also an intranasal"/>
 <result pre="influenza infections. European Medicines Agency-approved Fluenz® is also an intranasal" exact="influenza" post="vaccine consisting of four live-attenuated strains (H1N1, H3N2, and"/>
 <result pre="vaccine consisting of four live-attenuated strains (H1N1, H3N2, and two" exact="influenza" post="B virus) developed to prevent influenza infection in individuals"/>
 <result pre="(H1N1, H3N2, and two influenza B virus) developed to prevent" exact="influenza" post="infection in individuals older than 24 months until the"/>
 <result pre="of pandemic A/California/7/2009 (H1N1) influenza. Noted that these existing intranasal" exact="influenza" post="vaccines are all cold adapted, but heat sensitive, allowing"/>
 <result pre="Song Z, et al. A new coronavirus associated with human" exact="respiratory disease" post="in China. Nature [Internet]. 2020;579(7798):265–9 Available from: http://www.nature.com/articles/s41586-020-2008-3. 2.LanJGeJYuJShanSZhouHFanSZhangQShiXWangQZhangLWangXStructure"/>
 <result pre="L, et al. Lethal infection of K18-hACE2 mice infected with" exact="severe acute respiratory syndrome" post="coronavirus. J Virol [Internet]. 2007;81(2):813–21 Available from: https://jvi.asm.org/content/81/2/813. 13.Gretebeck"/>
 <result pre="the glycoprotein of Marburg virus and the S protein of" exact="severe acute respiratory syndrome" post="coronavirus. J Virol [Internet]. 2004;78(21):12090–5 Available from: https://jvi.asm.org/content/78/21/12090. 15.Weingartl"/>
 <result pre="al. Immunization with modified Vaccinia virus Ankara-based recombinant vaccine against" exact="severe acute respiratory syndrome" post="is associated with enhanced hepatitis in ferrets. J Virol"/>
 <result pre="vaccine against severe acute respiratory syndrome is associated with enhanced" exact="hepatitis" post="in ferrets. J Virol [Internet]. 2004;78(22):12672–6 Available from: https://jvi.asm.org/content/78/22/12672."/>
 <result pre="prediction and molecular dynamics simulation of a fusion construct containing" exact="malaria" post="pre-erythrocytic vaccine candidate, PfCelTOS, and human interleukin 2 as"/>
 <result pre="al.Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses"/>
 <result pre="modification of monodisperse magnetite nanoparticles for improved intracellular uptake to" exact="breast cancer" post="cells. J Colloid Interface Sci [Internet]. 2005;283(2):352–7 Available from:"/>
 <result pre="of monodisperse magnetite nanoparticles for improved intracellular uptake to breast" exact="cancer" post="cells. J Colloid Interface Sci [Internet]. 2005;283(2):352–7 Available from:"/>
 <result pre="boerAHHagedoornPVanbeverRet al.Pulmonary immunization: deposition site is of minor relevance for" exact="influenza" post="vaccination but deep lung deposition is crucial for hepatitis"/>
 <result pre="for influenza vaccination but deep lung deposition is crucial for" exact="hepatitis" post="B vaccinationActa Pharm Sin B [Internet]2019961231124010.1016/j.apsb.2019.05.003 88.KulkarniPSRautSKDhereRMA post-marketing surveillance"/>
 <result pre="[Internet]2019961231124010.1016/j.apsb.2019.05.003 88.KulkarniPSRautSKDhereRMA post-marketing surveillance study of a human live-virus pandemic" exact="influenza" post="A (H1N1) vaccine (Nasovac ® ) in IndiaHum Vaccin"/>
 <result pre="in IndiaHum Vaccin Immunother [Internet].20139112212410.4161/hv.2231723442586 89.MutschMZhouWRhodesPBoppMChenRTLinderTSpyrCSteffenRUse of the inactivated intranasal" exact="influenza" post="vaccine and the risk of Bell’s palsy in SwitzerlandN"/>
 <result pre="palsy in SwitzerlandN Engl J Med [Internet]2004350989690310.1056/NEJMoa030595 90.MillerEAndrewsNStellitanoLStoweJWinstoneAMShneersonJet al.Risk of" exact="narcolepsy" post="in children and young people receiving AS03 adjuvanted pandemic"/>
 <result pre="children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009" exact="influenza" post="vaccine: retrospective analysisBMJ [Internet].2013346f79410.1136/bmj.f79423444425 91.ConnellTDCholera toxin, LT-I, LT-IIa and"/>
</results>
